Home > Healthcare > Pharmaceuticals > Finished Drug Form > U.S. Sex Reassignment Hormone Therapy Market

U.S. Sex Reassignment Hormone Therapy Market Trends

  • Report ID: GMI10815
  • Published Date: Aug 2024
  • Report Format: PDF

U.S. Sex Reassignment Hormone Therapy Market Trends

Increasing awareness and acceptance of sex reassignment treatments have emerged as pivotal drivers for the market, fostering significant growth in recent years. This shift is largely attributed to the growing visibility of transgender individuals in media, politics, and public discourse, which has helped demystify gender dysphoria and the importance of gender-affirming care.
 

  • High-profile figures like Laverne Cox and Caitlyn Jenner have brought transgender issues to the forefront, prompting more open discussions about the medical needs of the transgender community. Consequently, this increased visibility has translated into a greater understanding of sex reassignment treatments, leading to a rise in demand for hormone therapy as a key component of gender transition.
     
  • A 2023 survey by the American Society of Plastic Surgeons found that 56% of transgender patients reported easier access to hormone therapy, reflecting the progress made in healthcare inclusivity.
     
  • Moreover, educational initiatives and advocacy efforts have played a significant role in increasing awareness among individuals and healthcare providers. Organizations like the World Professional Association for Transgender Health (WPATH) have established guidelines that help ensure transgender individuals receive appropriate and affirming care. This has led to a broader acceptance of hormone therapy as a legitimate and necessary treatment for gender dysphoria, further driving market growth.
     
  • The overall trend towards greater acceptance is evident, as seen in the increasing number of states implementing protections for transgender healthcare. For instance, California and New York have enacted legislation that mandates insurance coverage for gender-affirming treatments, including hormone therapy. This growing acceptance and institutional support are expected to continue driving the market, making these treatments more accessible and widely accepted.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. sex reassignment hormone therapy industry size was USD 1.6 billion in 2023 and will grow at a 5.3% CAGR between 2024 and 2032 due to increasing societal acceptance and legal recognition of transgender individuals.

The hospital pharmacies segment held USD 671.1 million in 2023, driven by their pivotal role in providing comprehensive and personalized care.

East South Central U.S. sex reassignment hormone therapy industry achieved USD 417.4 million in 2023, attributed to its significant healthcare infrastructure and increasing acceptance of transgender healthcare services.

ASCEND Therapeutics US, LLC, BIOTE MEDICAL, LLC, Eli Lilly and Company, Endo International plc, Novartis AG, Noven Pharmaceuticals, Inc., Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc., among others.

U.S. Sex Reassignment Hormone Therapy Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 30
  • Countries covered: 1
  • Pages: 100
 Download Free Sample